Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 44

of 'Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy'

Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab.
Brugger W
Tumori. 2010 May-Jun;96(3):473-7.
AIMS AND BACKGROUND: There are only limited data on the safety and efficacy of panitumumab in patients who experienced severe infusion reactions during cetuximab antibody therapy.
CASE REPORT: We report the case of a 69-year-old woman with chemotherapy-refractory metastatic colorectal cancer who received single-agent cetuximab treatment but experienced a severe reaction during the first infusion, despite premedication with corticosteroids/antihistamines. Cetuximab was discontinued and treatment with panitumumab initiated approximately 14 days later (without premedication); no infusion reactions occurred and there was a rapid improvement in her general condition. She experienced a partial response that was sustained for 7 months before progression.
CONCLUSIONS: This case supports the use of panitumumab in patients with chemotherapy-refractory metastatic colorectal cancer and suggests that panitumumab may be used in some patients with prior infusion reactions to cetuximab.
Schwarzwald-Baar Clinic, Villingen-Schwenningen, Teaching Hospital, University of Freiburg, Germany. wolfram.brugger@sbk-vs.de